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Abstract Treatment of amyotrophic lateral sclerosis (ALS)
has been fueled, in part, by frustration over the short-
comings of the symptomatic drugs available, since these do
not impede the progression of this disease. Currently, over
150 different potential therapeutic agents or strategies have
been tested in preclinical models of ALS. Unfortunately,
therapeutic modifiers of murine ALS have failed to be
successfully translated into strategies for patients, probably
because of differences in pharmacokinetics of the thera-
peutic agents, route of delivery, inefficiency of the agents to
affect the distinct pathologies of the disease or inherent
limitations of the available animal models. Given the
multiplicity of the pathological mechanisms implicated in
ALS, new therapies should consider the simultaneous
manipulation of multiple targets. Additionally, a better
management of ALS therapy should include understanding
the interactions between potential risk factors, biomarkers
and heterogeneous clinical features of the patients, aiming
to manage their adverse events or personalize the safety
profile of these agents. This review will discuss novel
pharmacological approaches concerning adjusted therapy
for ALS patients: iron-binding brain permeable multimodal
compounds, genetic manipulation and cell-based treatment.
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Introduction
Amyotrophic lateral sclerosis (ALS), commonly referred as
‘Lou Gehrig’s disease’ is a relentlessly progressive, neuro-
logical disorder with an estimated uniform prevalence of 4–6
cases per 100,000 in Western countries, where it is 50–100
times higher than elsewhere in the world [1, 2]. The onset of
ALS is most common in midlife between 45–65 years of
age, with a typical disease course of one to 5 years [2].
The progressive stage of this disease is characterized by
specific degeneration of both upper and lower motor neurons
in the brain, brainstem and spinal cord, resulting in paralysis
due to muscle weakness and atrophy [3]. In a small
percentage of cases, dementia is observed [4]. The
majority of patients die within 3–5 years of symptom
onset because of respiratory failure. Only 10% of all ALS
cases are characterized as genetic familial ALS (fALS),
whereas the vast majority is of unknown etiology and
classed as sporadic ALS (sALS) [5, 6]. Both forms of ALS
are clinically and pathologically similar, suggesting a
possible common pathogenesis and final pathway of
neurodegeneration [7] though sALS generally develops
later than fALS [8].
However, the underlying cause of ALS remains elusive,
as well as the development of the chain of events leading to
this disease, contributing to the lack of effective therapy.
Treatment of ALS has been fueled in part by frustration
over the shortcomings of the symptomatic drugs available,
since they are incapable of slowing down disease progression
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and neuronal degeneration. Currently, over 150 different
potential therapeutic agents or strategies have been tested in
transgenic ALS mice according to published reports [9].
This list involves 108 pharmacotherapies, 14 gene or
antisense therapies, 9 cell transplantations, 3 immunizations
and 7 dietary or lifestyle regimens. The pharmacotherapy
spectrum encompasses antioxidants, anti-excitotoxins, anti-
aggregation compounds, anti-apoptotics, anti-inflammatories
and neurotrophic agents. However, most of the candidates
have been reported to have limited therapeutic benefits and
only modest effects on survival of ALS patients. In addition,
therapeutic modifiers of murine ALS have failed to be
successfully translated into strategies for patients, probably
because differences in pharmacokinetics of the therapeutic
agents, route of delivery, inefficiency of the agents to affect
the distinct pathologies of the disease or inherent limitations
of the available animal models [10, 11]. For example,
antioxidant treatments such as vitamin E, N-acetylcysteine,
and L-methionine demonstrated to delay the disease onset
and progression in an ALS animal model [12], show a lack
of clinical efficacy in randomized controlled trials in 830
ALS patients [13]. Similarly, systemic administration of the
anti-apoptotic compound, minocycline, a second-generation
tetracycline antibiotic, that can delay the symptom onset in
ALS animal model [14], has been reported to fail in a
multicenter, phase III, randomized, controlled trial in more
than 400 ALS patients [15]. Regrettably, riluzole, an anti-
glutamatergic agent, demonstrated to inhibit the presynaptic
release of glutamate and the only drug for the treatment of
ALS approved by the US Food and Drug Administration
(FDA), is reported to have limited therapeutic benefits and
only modest effects on survival of ALS patients [16].
To improve ALS disease management, therapy should
include understanding of the interactions between potential
risk factors, biomarkers and heterogeneous clinical features
of the patients, with the aim of improving management of
their adverse events or personalizing the safety profile of
these agents. This knowledge may offer a superior
distinction of the pathological profiles among individuals
or groups of ALS patients and in turn lead to new-focused
therapeutic clinical trials.
The clinical aspects and advanced therapies in personal-
ized treatment of ALS patients are beyond the scope of this
review and thoroughly discussed by Nefussy and Drory in
the current issue [17]. The current review will discuss novel
therapeutic approaches employed in preclinical models of
ALS, including iron-binding brain permeable compounds
possessing multimodal neuroprotective activities and genetic
and cell-based therapies. These therapeutic approaches take
into account the various challenging features of this disease
and the interplay of genetic and environmental risk factors,
to provide superior efficacy in translation from preclinical
studies to the clinic.
Multifunctional-iron chelating therapeutic strategies
in ALS
Current therapeutic strategies suggest that drugs acting at a
single target may be insufficient for the treatment of
multifactorial neurodegenerative diseases, such as Parkinson’s
disease (PD), Alzheimer’s disease (AD) and ALS, all
characterized by the coexistence of multiple pathologies.
The molecular pathogenesis of ALS is poorly understood,
contributing to the lack of effective system-based therapies to
treat this disease. Investigations have inferred that ALS is a
multifactorial and multisystemic disease, that arises from
combination of several mechanisms which act through
concurring damage inside motor neurons and their neighbor-
ing nonmotor cells. These include genetic factors; oxidative
stress (OS) damage; mitochondrial malfunction; protein
misfolding and aggregation; defective axonal transport;
neurofilament aggregation; increased glutamate excitotoxic-
ity; neuroinflammation; deficits in neurotrophic factors and
dysfunction of cell signaling pathways [2, 5, 18].
The effect of OS within neurons has been studied mainly
in the G93A-superoxide dismutase (SOD)1 transgenic
mouse model- related fALS (which develops symptoms
and pathology similar to those of ALS patients); however,
the roles of OS in sALS remain obscure. Recently, a role of
iron in OS-induced motor neuron damage has been
suggested. It is well established that ionic iron, participates
in the Fenton chemistry and reacts with hydrogen peroxide
to produce reactive oxygen species (ROS), displays
elevated iron levels in the central nervous system (CNS)
of both sporadic and familial forms have been reported [19,
20]. Indeed, a recent clinical report described a patient, who
was diagnosed with neurodegeneration and brain iron
accumulation, but had clinical criteria for frontotemporal
dementia and picture of ALS [4]. Recently, a defect in the
Hfe gene, which has been previously associated with iron
overload diseases, hemochromatosis and Alzheimer’s dis-
ease (AD), is currently associated with ALS [21]. The
protein normally made by the Hfe gene is thougt to limit
the uptake of iron by cells, to protect against OS and
possibly to dampen inflammatory reactions. An increased
incidence of the Hfe mutation has been reported in ALS
patients [22]. The presence of this mutation was shown to
disrupt expression of tubulin and actin at the protein levels
potentially consistent with the disruption of axonal trans-
port seen in ALS and associated with a decrease in SOD1
expression [22]. In support for the involvement of iron in
ALS pathology, the iron-responsive protein transferrin, was
localized in Bunina bodies of spinal cord neurons from
ALS patients [23, 24], suggesting its involvement in the
formation of these inclusions.
In accordance with the human studies, in the G93A-SOD1
transgenic mouse model, the expression of ferritin was
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induced at late stages of the disease, indicating high iron
concentrations [15]. Interestingly, in transgenic mice
expressing the wild type SOD1 or SOD1-active mutant
enzyme, G93A-SOD1, the expression of transferrin receptor
(TfR) and iron regulatory proteins 1 (IRP1), a positive
transcriptional regulator of TfR [25], were positively modu-
lated in response to increased SOD1 mutation [23]. Jeong
and collaborators [26] have recently described dysregulation
of iron homeostasis mechanism in the CNS in the G37R-
SOD1 transgenic mice model of ALS, suggesting that iron
chelating therapy might be useful for the treatment of ALS.
In support, iron-binding porphyrin (a catalytic antioxidant)
treatment has extended survival and increased neuronal
survival in the spinal cord in G93A-SOD1 mice [27].
Noticeably, drug therapy of neurodegenerative diseases
with multifunctional compounds embracing diverse bio-
logical properties with single bioavailability and pharma-
cokinetic metabolism, will have a pronounced advantage
over individual-target drug or cocktail of drugs. Based on
this reasoning, Youdim and collaborators [28, 29] have
designed and synthesized several chimeric compounds, by
amalgamating the neuroprotective propargyl moiety of the
anti-Parkinson’s drug/ irreversible selective monoamine
oxidase (MAO)-B inhibitor, rasagiline [N-propargyl-1R
(+)-aminoindan], Azilect (Teva Pharmaceutical Netanya
Industries, Ltd. Israel) into the antioxidant-iron chelating
skeleton of the 8-hydroxyquinoline derivative of VK-28,
to produce several multiomodal compounds for combating
neurodegenerative diseases, such as ALS.
In searching for the superlative neuroprotective agents in a
series of multifunctional iron chelators, the compound M30
(5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline)
(Fig. 1) was found to be a most potent iron chelator,
nontoxic, brain permeable, displaying highly effective
inhibition of MAO-A and -B activities in vitro and in
vivo and iron-induced membrane lipid peroxidation [28–
32]. Additionally, M30 was found to invoke a wide range
of pharmacological activities, including a neurorescue
response, a protective potency against OS insults and
regulatory action on neuronal differentiation and neurite
outgrowth in various neuronal cell lines [33–36]. In in vivo
studies, M30 possesses a significant neuroprotective as well
as neurorescue activity against N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) neurotoxicity in mice [30, 31].
In addition, both M30 and VK28 were found to prevent
the loss of mice tyrosine hydroxylase (TH) positive neurons,
induced by post-intra-nigral injection of lactacystin, signif-
icantly improve behavioral performances and attenuate
inhibition of ubiquitin-proteasome activity, iron increase
and microglial activation in the ipsilateral substantia nigra
(SN) [37].
Given the diversity of pathological mechanisms impli-
cated in ALS, which suggested that multiple pathways may
contribute to this disease [38], new ALS therapies may
consider a simultaneous manipulation of multiple targets.
Indeed, combination treatments or polypharmacy, targeting
different disease mechanisms have consistently shown
superior efficacy in transgenic ALS mice, such as the
combination of rasagiline with riluzole [39].
Multimodal iron chelating compounds,
M30 and HLA20
Neuroprotective effects on cell survival and signaling
cascades in cell cultures
In a recent experimental study of ALS, M30 and an additional
newly designed multifunctional compound, HLA20 (5-[4-
propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline) [40]
(Fig. 1) were demonstrated to possess multiple pharmaco-
logical activities in NSC-34 cells, a widely used mouse
motor neuron-like cell line [36]. Initially, M30 and HLA20
were demonstrated to acquire a protective potency after
exposure of cultured NSC-34 cells to the OS insults,
hydrogen peroxide (H2O2) and peroxynitrite generator, 3-
morpholinosydnonimine (SIN-1) [36], previously shown to
be associated with motoneuron degeneration in ALS [41, 42].
This observation is consistent with previous studies showing
that M30 decreased apoptosis of SH-SY5Y neuroblastoma
cells in a neurorescue, serum deprivation model, via various
protective mechanisms, including reduction of the pro-
Fig. 1 Chemical structure of the novel brain permeable, multifunction-
al iron chelating compounds and the natural iron chelator, EGCG. a
M30 (5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline) and
HLA20 (5-[4-propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline),
restrained the propargyl moiety. b The major polyphenolic com-
pound of green tea, (−)-epigallocatechin-3-gallate, EGCG
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apoptotic proteins, Bad and Bax and inhibition of the
apoptosis-associated phosphorylated H2A.X protein (Ser
139) and caspase-3 activation [33]. Since N-propargylamine
and rasagiline confer neuroprotective/neurorescue effect via
activation of protein kinase C (PKC) and mitogen-activated
protein kinase (MAPK) signaling pathways, coupled to
pro-survival Bcl-2 family members and mitochondrial
membrane stabilization [43–45], it can be assumed that
the neuroprotective effect of the novel multifunctional
drugs, demonstrated in NSC-34 cells, may be partially
associated with their propargyl moiety.
Effect on iron homeostasis-related proteins
and hypoxia-inducible factor (HIF) pathway in cell cultures
The iron complexing moiety, embedded in the novel
multifunctional iron chelating drugs may favorably
influence cell survival by reducing the levels of ROS
and reactive nitrogen species (RNS), due to neutraliza-
tion of excessive free-reactive Fe2+. An alternative
pathway of protection by iron chelators may include the
inhibition of the iron-dependent hypoxia-inducible factor
(HIF)- prolyl 4-hydroxylases (PHDs), enzymes that regulates
HIF stability (Fig. 2) [46]. Indeed, PHDs have been
suggested as an additional target for neuroprotection in
various neurodegenerative diseases. Inhibition of HIF-PHDs
prevents the hydroxylation and subsequent degradation of
HIF-1α [47]. Stabilization and nuclear localization of HIF-
1α results in heterodimerization with its partner HIF-1β,
binding to the hypoxia-response element in the gene
regulatory regions, and subsequent transcriptional up-
regulation of established protective genes, such as erythro-
poietin, vascular endothelial growth factor (VEGF),
p21waf1/cip1, glycolytic enzymes (e.g. aldolase and
enolase 1) as well as iron homeostasis-related proteins
(e.g, TfR) [47–49]. Siddiq et al. [47] used an in vitro
model of OS to correlate the protective effects of iron
chelators and small molecules and peptides that don’t bind
iron, but do inhibit the PHDs, with their ability to activate
HIF-1. This model has been further supported by the
observation that the prototype iron chelating drug, desfer-
rioxamine (DFO), was neuroprotective in hippocampal
neuronal culture exposed to oxygen and glucose depriva-
tion, in addition to OS and excitotoxicity damage, while
this protection was prevented by blockade of HIF-1α with
antisense oligonucleotide transfection [50].
In accordance, recent study has demonstrated that
M30 and HLA20 induced mRNA expression of HIF-1α
and enhanced the protein levels of HIF-1α and its
nuclear translocation in NSC-34 cells [36]. Furthermore,
M30 and HLA20 significantly increased the levels of the
endogenous HIF-1-dependent genes, enolase 1, VEGF,
brain derived neurotrophic factor (BDNF) and TfR in
NSC-34 cells (Fig. 2) [36]. Although VEGF was once
considered to be only a specific angiogenic factor,
emerging evidence indicates that it also has direct effects
on neuronal cells and protects motoneurons from cell
death induced by various insults, such as OS, hypoxia/
hypoglycemia, glutamate-excitoxicity and serum depriva-
tion [51]. Deletion of the hypoxia-responsive element in
the promotor region of the VEGF gene can cause motor
degeneration in mice and low-VEGF producing alleles of
the VEGF gene are associated with motoneuron degener-
ation in human ALS, suggesting that VEGF is a modifier
of motoneuron degeneration in human ALS [52–54].
Although there is evidence for and against the role of
Fig. 2 Neuroprotective targets
involved in mechanism of action
of the multifunctional iron
chelating compounds (e.g. M30,
HLA20). Full explanation is
discussed in the text. Abbrevia-
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VEGF in ALS etiopathogenesis, the literature has widespread
interest in developing VEGF-based therapies for motoneuron
degenerative disorders, raising new hope for the treatment of
ALS and other neurodegenerative diseases. Besides regulat-
ing VEGF, HIF-1 has been also shown to promote glycolytic
enzyme gene expression and consequent aerobic glycolysis
[55, 56]. Recent studies have demonstrated that a shift in
energy generation from glucose oxidation in mitochondria to
aerobic glycolysis is associated with resistance to OS [57].
Thus, by inducing glycolytic enzyme expression, iron
chelators may reduce the ambient free radical burden of
neurons by enabling the cell to generate more energy
glycolytically and minimize deleterious consequences of
mitochondrial glucose oxidation. Taken together, it can be
suggested that regulation of HIF-1α expression and its related
genes may constitute an additional pathway underlying the
neuroprotective effect of M30 and HLA20.
In addition, it has been reported that phosphatidylinositol-
3-kinase (PI3K)/ protein kinase B (AKT) signaling plays an
important role in regulating HIF-1α expression [58, 59].
Indeed, both M30 and HLA20 markedly increased the
amount of phospho-AKT and phosphor- glycogen synthase
kinase 3 (GSK-3)β (at ser-9) [60] in NSC-34 cells,
suggesting that both drugs induced activation of AKT
followed by phosphorylation (inactivation) of GSK-3β
(Fig. 2) [36].
Induction of neurite outgrowth and differentiation
in cell cultures
Another important characteristic aspect of M30 and HLA20
is their ability to induce differentiation, cell elongation and
stimulate neurite outgrowth of NSC-34 motoneuron cells
[36]. These morphological modifications were accompa-
nied by an increase in the immunoreactivity of the neuronal
marker Growth-associated protein, GAP-43, and decrease
in cyclin D1 expression [36], in accordance with results of
previous studies, demonstrating that M30 induced a
neuritogenic effect and triggered cell cycle arrest in G0/
G1 in rat pheochromocytoma PC12 and human SH-SY5Y
neuroblastoma cell lines [33]. Indeed, many cell cycle
regulating factors require iron for their function [61, 62].
Thus, an inhibitory effect of the novel iron-chelator
compounds on cell cycle reentry [33], may trigger the
process of differentiation through various iron-associated
biological events [63]. In addition, the effect of the
multifunctional drugs on motoneuron differentiation may
be associated with their propargyl moiety, since N-
propargylamine and rasagiline were shown to up-regulate
BDNF and glial cell line-derived neurotrophic factor
(GDNF) gene expression in PC12 cells [43, 45]. In in vitro
studies in NSC-34 cell, M30 and HLA20 were demonstrat-
ed to induce mRNA levels of BDNF, which is a well
recognized neurotrophic factor for motoneurons [36, 64–
66]. Motor neuron differentiation, induced by M30 and
HLA20, was shown to be modulated by inhibitors of ERK/
MAPK and PKC signaling pathways (Fig. 3) [36]. In
results, complementary to inhibition studies, we found that
the drugs significantly increased the immunoreactivity of
phosphorylated MAPK and PKC in NSC-34 cells, further
indicating the involvement of both ERK and PKC
activation [36].
Neuroprotective effects in mouse model of ALS
Treatment with M30 provided clear benefits in the fast-
progressing strain of G93A-SOD1 mutant ALS transgenic
mice [67] even when the treatment was initiated relatively
advanced stage of the disease (at day 70th post-natal) [36].
Oral administration of M30 (1 mg/kg, 4Xwk) resulted in
delaying the onset of motor dysfunction (the average age of
onset was 107±3 days in the control group, while 112±
4 days in the M30-treated group; n=14–16/group; p<0.001;
log -rank Mantel-Cox test) and in significantly increasing
their survival (an increase in survival by M30 treatment from
124±6 to 134±12 days; n=14-16/group; p<0.025; log -rank
Mantel-Cox test) (Fig. 4) [36]. In a supplementary study
performed in G93A-SOD1 mice, initiated at presymptomatic
stage of the neurological dysfunctions, M30 was demon-
strated to reduce spinal motor neuronal loss (submitted for
publication). M30 also inhibited the inflammatory-related
factor, tumor necrosis factor-α (TNFα) by suppressing the
glial activation, as well as reduced TAR-DNA binding
protein (TDP-43), which is a major ubiquitinated inclusion
of ALS inclusions [68, 69].
Natural multifunctional iron chelating compound,
EGCG
Naturally multifunctional occurring polyphenols, in particu-
lar, the major component of green tea, (−)-epigallocatechin-3-
gallate (EGCG) (Fig. 1) has been indicated as novel and
promising therapeutic approach for treating neurodegenera-
tive disease, including AD, PD and ALS. Indeed, several
studies of acute and chronic EGCG administration in
different cellular and animal models of neurodegeneration,
demonstrated various novel molecular targets, including, the
MAPK/ PKC and the PI3K/AKT signaling pathways;
survival genes and proteins associated with mitochondrial
function [70]. EGCG was demonstrates to protect ventral
spinal cord 4.1 cells (VSC 4.1), motoneuron–neuroblastoma
hybrid cell line, wild-type and G93A mutant cells, from
H2O2-induced cytotoxicity and affected upstream signaling
through the PI3K/Akt, GSK-3 pathway, as well as down-
stream cascade involved in cytochrome c release and
EPMA Journal (2010) 1:343–361 347
caspase-3 activation [71]. In accordance, oral administration
of EGCG to G93A-SOD1 mutant transgenic mice, beginning
from a pre-symptomatic stage, significantly prolonged the
symptom onset, delayed the onset of disease and extended
life span [71–73]. Additionally, EGCG increased the number
of motor neurons, diminished microglial activation, reduced
immunohistochemical reaction of NF-kappaB and cleaved
caspase-3, as well as reduced protein level of iNOS and NF-
kappaB in the spinal cords of G93A-SOD1 mutant trans-
genic mice [73].
Genetic and cellular therapeutic approaches in ALS
patients and animal models
The vast majority of ALS cases have not been associated
with genetic factors. However, approximately 2% of all
known ALS cases are attributed to mutations in the zinc/
copper superoxide dismutase (SOD1) gene [6]. To date,
over 100 mutations associated with fALS have been
mapped to the SOD1 gene. One of the most prevalent
mutations is the G93A variant, in which the amino acid
glycine is replaced by alanine at position 93. This
information was used in developing animal models of
ALS; the first and most commonly used model is of
transgenic rodents harboring the G93A mutation. These
animals develop a pathophysiological condition resembling
ALS, presenting with hindlimb weakness at 3 to 4 months
of age and progressive paralysis culminating in death at the
age of 4 to 5 months. The pathological features of the
disease resemble human neurologic diseases, including loss
of large spinal cord motoneurons and robust spinal
astrogliosis and microgliosis [5, 67]. Other genes linking
Fig. 3 Attenuation of the neuritogenic effect of M30 and HLA20 by
specific inhibitors of PKC and MAPK/ERK kinase (MEK). NSC-34
cells were incubated with PKC inhibitor GF109203X (2.5 µM) or
MEK inhibitor PD98059 (10 µM) for 1 h before administration of
M30 (10 µM) or HLA20 (10 µM) for a further 24 h. The cells were
fixed and permeabilized for GAP-43 detection. a The images are
representative fields from three independent experiments. b the
histogram represents averages of the differentiated cell percentages
(± SEM). One-way ANOVA followed by Student’s t-test was used for
statistic analysis. * p<0.001 vs. respective controls; # p < 0.001 vs.
M30 and HLA20 only (without inhibitors) treated cells. (Reproduced
from [36])
Fig. 4 Effect of M30 treatment on motor dysfunction onset, survival
time, motor deficits and weight in G93A-SOD1 mutant ALS transgenic
mice. Mutant G93A-SOD1 mice were treated by the oral gavage method
with vehicle (control) or M30 (1 mg/kg) four times a week starting from
the 70th day after birth and continuing until death. Plots present
cumulative probability of a the symptoms onset (n=13–16 per group;
p<0.001; log -rank Mantel-Cox test) and b overall survival (n=13–16
per group; p<0.025; log -rank Mantel-Cox test) against the age of the
mutant mice. Histograms present c mean onset (days) and d mean
survival (days) of vehicle- or M30-treated G93A-SOD1 mice. Values
are means±SEM (n=13–16 per group; *p<0.05, ** p<0.001 vs.
control group; one-way ANOVA). e Overall neurological deficit scores
vs. the age of animals. The total neurological deficits were determined
from four independent tests (rotarod performance, postural reflex,
screen grasping and tail suspension behavior). Total score of 12
represent a complete loss of motor function. Values are means±SEM
(n=13–16 per group). fWeight vs. the age of animals. Values are means
±SEM. (Reproduced from [36])

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to fALS include alsin (ALS2), senataxin (ALS4), vesicle
associated membrane protein (VAPB, ALS8), angiogenin and
a mutation in the p150 subunit of dynactin [2]. Recently,
mutations in TARDBP gene, encoded the TAR-DNA
binding protein TDP-43 and located on chromosome
1p36.22, have been reported to be associated with fALS
and sALS [2].
In the next section, we will focus on genetic therapies,
cell replacement therapies and their combination. We will
further review experiments, performed predominantly in
the SOD1 rodent ALS models and later adapted for clinical
trials (Fig. 5; Table 1).
Adeno-associated viruses
Adeno-associated viruses (AAVs) are small single strand
DNA genome encapsidated viruses, which require helper
viruses for successful infection and are therefore not
themselves pathogenic [117, 118]. Recombinant AAVs
(rAAVs) are produced by replacing their pathogenic viral
DNA with the gene of interest.
Injecting rAAVs containing either IGF-1 or GDNF into
respiratory and motor limb muscle terminals of SOD1
G93A mice delayed disease onset, prolonged life and
moderated disease progression. IGF-1 was found to
perform more potently than GDNF. It was further estab-
lished that the rAAVs selectively transfected motoneurons
without infecting neighboring glia cells. To assess the
importance of rAAVs retrograde delivery into the central
nervous system (CNS), SOD1 mice were transfected with
recombinant lentiviruses (rLVs) containing IGF-1 which
were not retrogradely transported and were found to
increase survival to a lesser extent than rAAV-IGF-1 [90].
Similar results were obtained when rAAVs containing IGF-
1 were delivered to the deep cerebellar nuclei [89]. Spinal
cord infection was accompanied by a sexual bias predom-
inantly effecting male mice [91, 92]. Additional research on
rAAVs carrying GDNF, injected intramuscularly, further
emphasized its therapeutic potential, as long term GDNF
expression in the CNS, a delay in disease onset, an
amelioration in disease progression and a prolongation of
life expectancy, were obtained [93, 119].
Neurotrophic factors are not the only genes that can be
delivered using viral vectors. Bcl-2 an anti-apoptotic
protein has previously been delivered to the lumber spinal
cord of SOD1 G93A mice using a rAAV construct.
Intraspinal injection of these rAAVs resulted in sustained
motoneuron Bcl-2 expression, delayed disease onset and
significantly increased the number of surviving motoneur-
ons at disease end-stage, but was ultimately unable to
prolong survival [94]. This represents an interesting
alternative for gene selection in AAV based gene therapy
in ALS. However, when considering this approach we must
be extremely vigilant regarding the transfected cells, as the
effect of Bcl-2 might be a double edged sword, protective
in non-dividing, degeneration prone motoneurons, yet
potentially oncogenic in other cells.
rAAVs are emerging as a prominent vector for neuro-
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 (E) rAAV-IGF-1, rAAV-
GDNF, LV-VEGF, TTC, IGF-
1:TTC, GDNF:TTC, hMSCs 
secreting GDNF 
   
Fig. 5 A schematic representation of methods allowing local delivery
of neurotrophic factors and cellular transplantations performed in ALS
animal models and patients. a Represents the cisterna magna. b Refers
to the CSF. c Concerns intraspinal treatment. d Indicates the spinal
intrathecal space. e Pertains to the intramuscular space. Abbreviations;
human mesenchymal stem cells (hMSCs), human neuronal progenitor
cells (hNPCs), recombinant Adeno-associated virus (rAAV), lentivirus
(LV), human neuronal stem cells (hNSCs), glial restricted precursors
(GRP), tetanus toxin heavy chain (TTC), fusion protein of IGF-1 and
TTC (IGF-1:TTC), fusion protein of GDNF and TTC (GDNF:TTC)
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Table 1 An overview of several genetic and cellular therapeutic approaches relating to ALS patients and animal models





Intrathecal administration No clinical or survival benefits. [74–76]
Recombinant IGF-1 Clinical trails ALS
patients.
Subcutaneous administration American trial: slower progression
of functional impairment.
[77, 78]
European trial: no clinical benefits.
Recombinant IGF-1 Clinical trails ALS
patients.





Subcutaneous injections No beneficial clinical results, high
dose CNTF administration was
accompanied by severe adverse
reactions and an increased
number of deaths.
[80–82]
Human MSCs Clinical trails ALS
patients.
Intraparenchymal autologous
transplantation at the thoracic
level of the spinal cord
Contradicting results of ether slight
clinical improvement or no
clinical benefits.
[83, 84]
Human HSCs Clinical trails sporadic
ALS patients
Post-irradiation transplantation
with a sibling’s HSCs








Clinical benefits have not been
reported.
[86–88]
rAAV-IGF-1 SOD1 G93A mice rAAV-IGF-1 at respiratory and
motor limb muscles or deep
cerebellar nuclei
Delayed disease onset, prolonged
life and moderated disease
progression.
[89, 90]
rAAV-IGF-1 SOD1 G93A mice rAAV-IGF-1 Spinal cord
infection
Delayed disease onset, weight loss,
decline in hindlimb grip strength
and increased survival was
observed in male but not female
mice.
[91, 92]
rAAV-GDNF SOD1 G93A mice rAAV-GDNF at respiratory and
motor limb muscles
Delayed disease onset, prolonged
life and moderated disease
progression.
[93]







rAAV-Bcl-2 SOD1 G93A mice Lumber spinal cord
rAAV-Bcl-2 infection




LV-GDNF SOD1 G93A mice and
facial motoneurons
axotomy model.
LV-GDNF lumber spinal cord
and facial nucleus injections
Rescue of motoneurons in the
facial nucleus. No effect on
spinal motoneurons.
[95, 96]
LV-VEGF SOD1 G93A mice LV-VEGF infection at muscle
terminals




TTC SOD1 G93A mice Intramuscular injections of
naked TTC DNA
Delayed onset of symptoms and
functional deficits, improved
spinal motor neuron survival, and
prolonged lifespan.
[98]
IGF-1:TTC SOD1 G93A mice Intramuscular and intrathecal
injections of soluble IGF-1:
TTC protein
No significant clinical effect. [99]
GDNF:TTC SOD1 G93A mice Intramuscular injections of
soluble GDNF:TTC protein
Mild survival prolongation. [100]
Human NSCs SOD1 G93A rats Lumbar spinal cord
transplantation
Delayed disease onset and




SOD1 G93A rats GRP transplantation at cervical
spinal cord respiratory motor
neuron pools
Extended survival and disease
duration, attenuated motor
neuron loss and moderated
decline in forelimb motor and
respiratory functions.
[103, 104]
Human MSCs SOD1 G93A mice and lumber spinal cord, cisterna Extended survival, reduced [105–107]
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many advantages, which include rare vector sequence
integration into host genome, efficient transfection of both
dividing and non-dividing cells, long-term gene expression,
low risk of toxicity, and minimal stimulation of the host
immune response. The existence of several serotypes allows
differential targeting of specific CNS cell populations [92].
However, they are limited by the relatively small amount of
DNA they can encapsulate, thus not suitable for larger
genetic constructs [118].
Lentiviruses
Lentiviruses (LVs) are the most complex viruses in the
retroviral family and are particularly suitable for CNS
related genetic therapy. Lentiviral vectors have relatively
large RNA packing capacity. They can efficiently transfect
not only dividing but also non dividing cells, such as
neurons. LVs can reverse transcribe their RNA into the host
cell’s DNA, thus promoting stable and long term expression
of the gene of interest [117, 120–122].
Recombinant LVs for gene therapy are produced
similarly to rAAVs. First, removal of as much of the viral
genes as possible occurs, then the desired expression
cassette is inserted. rLVs incapable of producing a
functional envelope can be pseudotyped with different
viruses to selectively direct the infection to the desired
cellular type and prevent secondary infection [123, 124].
Lumber spinal cord and facial nucleus injections of rLVs
incorporating the GDNF gene were found to significantly
rescue motoneurons in the facial nucleus, but did not
prevent spinal motoneuron loss, despite robust intraspinal
GDNF expression in SOD1 G93A mice and facial
motoneurons axotomy mice models [95, 96].
Injection of a recombinant rabies-G pseudotyped lentiviral
vector based on the equine infectious anemia virus encoding
the human vascular endothelial growth factor (hVEGF) gene
at several muscle terminals in SOD1 G93A mice, promoted
hVEGF expression in spinal cord motoneurons, delayed
disease onset, slowed disease progression and prolonged
survival [97].
Tetanus toxin heavy chain
Gene therapy can also be based on non-viral delivery of naked
DNA. It has been suggested that the non-toxic carboxy-
terminal fragment of the tetanus toxin heavy chain (TTC) can
act as a neuroprotective agent through the downregulation of
caspases 1 and 3. Intramuscular injections of naked DNA
encoding the TTC gene in SOD1 G93Amice delays the onset
of symptoms and functional deficits, improved spinal motor
Table 1 (continued)
Method of treatment Treated group Method of delivery Effect Reference
rats magna and CSF
transplantations
neuroinflammation; astrogliosis
and microgliosis and ameliorated
disease symptoms.
Human MSCs SOD1 G93A mice Post irradiation intravenous
administration
Delayed disease onset, delayed
disease progression and increased
lifespan.
[108]
Bone marrow cells A crossbred of PU.1−/−
mice and SOD1
G93A mice





Bone marrow cells SOD1 G93A mice Post-irradiation intra-bone
marrow grafts










SOD1 G93A mice and
rats





SOD1 G93A rats Muscle transplantations Delayed disease progression and




SOD1 G93A mice Intrathecal transplantation into
the lumber spinal cord
Delayed disease onset, slower





SOD1 G93A mice Intrathecal transplantation into
the cisterna magna
Enhanced motor neuron survival,




Abbreviations: MSCs Mesenchymal stem cells, NPCs neuronal progenitor cells, NSCs neuronal stem cells, GRP glial restricted precursors, rAAV
recombinant Adeno-associated virus, LV lentivirus, TTC tetanus toxin heavy chain, IGF-1:TTC fusion protein of IGF-1 and TTC, GDNF:TTC,
fusion protein of GDNF and TTC
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neuron survival, and prolonged lifespan [98]. TTC has also
been used as a platform for delivering IGF-1 and GDNF to
motoneurons. Intrathecal and intramuscular injections of a
soluble IGF-1: TTC fusion protein had no significant effect
on disease progression or survival in SOD1 G93A mice [99].
However, a slight increase in survival was noted when
similar intramuscular injections of a GDNF:TTC fusion
protein in SOD1 G93A mice were administered [100].
Genetic therapy approaches offer promising strategies
for delivering factors that might enhance the survival
chances of degeneration prone neurons in ALS. However,
it is not the only option: transplantation of whole cells
presents a viable and potent non-viral alternative.
Motor neuron replacement therapies
Motor neurons can be effectively derived from embryonic
stem cells (ESCs), neuronal stem cells (NSCs) and induced
pluripotent stem (iPS) cells [125–127]. The strategy for
treatment is to use these cells to replace the neurons
afflicted in ALS.
In several studies of neuronal transplantations, per-
formed in mice and rat models of ALS, a delay in disease
onset and a mild prolongation of life expectancy have been
observed [127–129].
It has been further shown that human NSCs grafted into the
lumbar spinal cord of SOD1 G93A rats, survive after
transplantation and present with predominantly neuronal
differentiation at the transplantation site. The grafts secrete
BDNF and GDNF, while forming functional synapses with
host motor and non-motor neurons. However, the differenti-
ated neurons do not develop into large motor neurons, but are
predisposed to a GABAergic phenotype. A mild delay in
disease onset and prolongation of life expectancy have been
observed [101, 102].
The limited in vivo axonal growth rate of grafted
motoneurons derived from ESC [126] hinders their viability
as candidates for replacement therapy in neurodegenerative
diseases such as ALS. The observed therapeutic effects of
neuronal stem cells in these experiments could be attributed
to their neuron to neuron trophic functions, such as
buffering glutamate levels and neurotrophic factor delivery
[102, 130]. In this case, whether motor neurons are best
suited to provide such effects, or whether other cell types,
such as astrocytes or microglia might provide a more potent
tool, must be discussed.
Astroglial replacement therapies
Astrocytic abnormalities participate in the degeneration
occurring in ALS [131–134]. Furthermore, astrocytes
possess potent neuroprotective potential [135]. Taken
together, these attributes render astrocytes interesting
targets in ALS related therapeutic strategies.
Transplantation of healthy rat and mice glial restricted
precursors (GRPs) around cervical spinal cord respiratory
motor neuron pools of SOD1 G93A rats, extended survival
and disease duration, attenuated motor neuron loss and
moderated the decline in forelimb motor and respiratory
functions. These effects correlated with reduced micro-
gliosis at the transplantation site and were severely hindered
when there was an absence of GLT1, the glutamate
transporter, in the cells grafted [103, 104].
These results suggest some potential for glial replacement
therapies that should be further investigated.
Another potential cellular source for motor neuron
protection is bone marrow derived mesenchymal stem cells
(MSCs). MSCs are self-renewing precursors that can be
differentiated in vitro to give rise to cells from multiple
lineages, including but not limited to neuron, oligodendro-
cyte and astrocyte like cells [136–138]. The use of MSCs as
the cellular source for stem cell based treatments not only
circumvents ethical concerns but further provides candi-
dates for autologous transplantation.
Several studies have shown that human MSCs (hMSCs),
survive after transplantation into the lumber spinal cord.
The cisterna magna and the CSF for long periods of time,
show limited migration into and within the spinal cord,
extend survival, reduce neuroinflammation; astrogliosis and
microgliosis, perform moderate differentiation into neurons
and astrocytes and ameliorate disease symptoms in mice
and rat SOD1 G93A models [105–107].
A different approach utilizes irradiation in order to
improve hMSC engraftment into the brain and muscles
[139]. Intravenous administration of hMSC in irradiated
pre-symptomatic SOD1-G93A mice has yielded similar
results to those previously mentioned, with additional
aspects of neuroglial differentiation and migration into the
brain and spinal cord parenchyma [108].
Mazzini et al. performed two clinical trials [83, 84] in
which MSC were autologously transplanted intraparenchy-
mally at the thoracic level of the spinal cord of ALS patients.
A total of 19 patients have been grafted in both experiments.
Patients were monitored for up to 4 years and no significant
acute or late side effects were evident. In most cases, no
modifications of spinal cord volume or other signs of spinal
or brain abnormal cell proliferation, were observed. However,
in 4 of the cases the spinal cord was tethered anteriorly and
posteriorly by postoperative scarring, producing marked
distortion of the cord due to traction. In the first trial, the
linear decline of the forced vital capacity was significantly
moderated in 4 of the 9 transplanted patients. However, in
second trial, slower deterioration was observed in only 2 of
the 10 grafted patients. The results suggest that hMSC might
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be considered as candidates for stem cell based treatment of
ALS. Moreover, intraspinal injection of MSCs showed no
long term adverse outcome. Additional clinical trials have
recently been launched.
Several mechanisms have been proposed to explain the
neuroprotective effect observed in transplantations of native
and differentiated MSC including cell replacement, immu-
nomodulation and trophic factor delivery. hMSC can be
further utilized as a platform for delivering neurotrophic
factors to target areas within the brain.
When considering the use of any stem cell grafts in the
future treatment of ALS, it must be noted that there is a risk
of tumor formation, non-specific differentiation and long
term toxic effect in these cells. One of the most prominent
advantages in selecting MSC in this respect is their relative
safety [140]. However, MSC derived from ALS patients
might sustain disease related damages [141, 142]. Thus,
autologous transplantations could be contaminated with cells
impaired in their ability to counteract disease pathophysiol-
ogy and result in loss of treatment effectivity. The limited
migration performed by hMSC means that transplantations
must take place in the already afflicted spinal cord of ALS
patients, posing a difficulty. These problems must be
addressed so as to be overcome in future treatments.
Microglia replacement therapies
Neurons and astrocytes are not the only cells suspected as
impaired in ALS. Microglia specifically, and the immune
system in general have been implicated in disease patho-
physiology [143–147]. In fact, exposure of primary rat
spinal cord cultures to immunoglobulin Gs (IgGs) isolated
from ALS patient lead to motor neuron apoptosis [143].
When intraperitoneally injected into healthy mice, ALS-
IgGs caused spinal cord microglia recruitment and motor
neuron degeneration [148, 149]. PU.1−/−mice are impaired
in their ability to develop myeloid and lymphoid cells
and therefore lack CNS microglia. These mice were
crossbred with SOD1 G93A mice and subsequently
transplanted with donor wild type bone marrow cells.
Donor cells differentiated into microglia and integrated
into the CNS. Grafted mice benefited from reduced
motoneuron degeneration, ameliorated disease progres-
sion and prolonged survival compared to mice trans-
planted with SOD1 G93A bone marrow cells and SOD1
G93A non-crossbred and non-transplanted mice [109].
Similar results were obtained when SOD1 G93A mice
were irradiated and then intra-bone marrow grafted with
wild type bone marrow cells [110] and when SOD1 mice
retro-ocularly received human umbilical cord blood cells
[111]. These findings prompted a clinical trial where 6
sporadic ALS patients underwent full body irradiation and
were then infused with a siblings' hematopoietic stem cells
(HSCs). Unfortunately, clinical benefits were not evident.
Nevertheless, the experiment was not completely unsuccess-
ful: grafted cells were found in post mortem autopsy brain
and spinal cord samples. Biases in HSCs engraftment were
observed, indicating that the cells gravitate towards areas of
motoneuron injury and neuroinflammation [85].
Yet, it is possible that with alternative grafting techniques
or cellular genetic engineering microglial cells therapeutic
potential might be enhanced.
Genetically altered cells
Using gene therapy technology to enhance the neuroprotec-
tive performance of stem cells prior to their transplantation
might offer a potential therapeutic tool.
Neuronal progenitor cells (NPCs), NSCs and hMSCs are
only a small portion of the cellular sources that can be
utilized for this purpose [112–116, 150, 151]. A vast variety
of genes could also be considered as genetic targets for
cellular enhancement, the most prominent of which are
neurotrophic factors and glutamate transporters.
Neurotrophic factors are a group of proteins essential for
neuronal development and survival. Delivery of appropriate
neurotrophic factors to the immediate environment of
afflicted neurons in ALS might improve their survival and
thus ameliorate disease progression and symptoms.
Glial cell line derived neurotrophic factor (GDNF)
Treatment with GDNF has shown interesting results in
several different neurodegenerative diseases models
[151–154]. However, spinal cord grafting of GDNF secreting
cells in ALS animal models appears to influence predomi-
nantly disease onset rather than progression [112–114].
Therefore, other neurotrophic factors might be better suited
for ALS. On the other hand, preliminary results suggest that
direct muscle delivery of GDNF, by genetically engineered
hMSC, delayed disease progression and improved the
overall life span [115]. In light of these results, the delivery
site of GDNF rather than the neurotrophic factor itself, must
be investigated as a factor in clinical outcome [155]. GDNF
based treatments might be suitable as complementary to
other neurotrophic factors.
Vascular endothelial growth factor (VEGF)
Deletion of the hypoxia response element sequence in the
vascular endothelial growth factor (VEGF) promoter in
otherwise healthy mice results in adult-onset muscle
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weakness due to the degeneration of lower motor neurons
innervating skeletal muscle fibers, reminiscent of the
clinical symptoms and neuropathology observed in ALS
[156]. Furthermore, crossbreeding of SOD1 G93A mice
with mice overexpressing VEGF in their motor neurons
attenuates motor impairment, delays motoneuron loss and
prolongs the survival of SOD1 G93A mice [157]. These
findings closely link ALS with VEGF and highlight its
therapeutic potential. Human NSCs (hNSCs) overexpress-
ing VEGF were intrathecally transplanted into the lumber
spinal cord of SOD1 G93A mice. Grafted cells survive for
at least 4 weeks in the diseased spinal cord and migrate into
the gray matter of the spinal cord. A small portion of
grafted cells differentiated into motoneurons. Transplanted
animals benefited from delayed disease onset, slower
decline of motor function and prolonged survival [116].
The manner by which these cells exert their therapeutic
effect remains to be determined. However, several
mechanisms might be proposed. VEGF's neurotrophic
function is one possibility, which includes anti-apoptotic
effect on motoneurons, encouragement of neovascularization
[158–160] and VEGF's protection against glutamate excito-
toxicity [161, 162]. While only few cells differentiated into
motoneurons, the possibility of neuronal replacement should
not be discounted altogether.
Insulin like growth factor type 1 (IGF-1)
Despite promising results in subcutaneous administration of
insulin like growth factor type 1 (IGF-1) in animal models
of ALS [163, 164], similar clinical trials have been found
wanting [77, 78, 165]. Yet, modest beneficial effects were
obtained in high dose intrathecal administration of IGF-1 in
ALS patients [79].
Localized and continues delivery of IGF-1, via genetically
enhanced cells could lower the necessary IGF-1 dosage thus
reducing side effects and improving the therapeutic outcome.
Recently, human NPCs (hNPS) have been adenovirally
infected with the IGF-1 gene, to induce IGF-1 secretion.
Transplantation of these cells into the cisternamagna of SOD1
G93A mice, showed enhanced motoneuron survival, but no
functional improvement or extension of life span [113].
Ciliary neurotrophic factor (CNTF)
Another factor that has been examined for therapy is the
ciliary neurotrophic factor (CNTF). Unfortunately, clinical
trials systemically delivering CNTF caused severe adverse
reactions in ALS patients [80–82]. In an attempt to reduce
unwanted CNTF related side effects, baby hamster kidney
cells were genetically engineered to overexpress CNTF,
encapsulated in a semispherical membrane and intrathecally
implanted in the lumber spinal cord of ALS patients. The
membrane allows for passage of nutrients and cell-released
therapeutic agents, but restricts diffusion of larger mole-
cules and cells, thus facilitating graft survival and enabling
the retrieval of the transplanted cells in the event of severe
side effects or oncogenic developments. A robust CNTF
presence could be detected for several weeks following
transplantation in the CSF of most patients. Grafts survive
for up to 20 weeks in the absence of immunosuppression, but
an antigenic reaction to bovine fetuin, a component of pre-
implantation medium was observed. However, neither CNTF
nor the presence of antibodies against bovine fetuin, elicited
any adverse side effects in the implanted patients. However,
clinical benefits have not been reported [86–88].
Glutamate transporters
A different approach to genetically engineered cells
considers increasing glutamate removal from the neuronal
environment rather than infusion of neurotrophic factors.
Glutamate is the main excitatory amino acid (a.a)
neurotransmitter in the human central nervous system
(CNS). It plays a major role in synaptic plasticity,
learning, development, cognitive functions and human
behavior [166–170]. However, when glutamate is not
properly controlled, it may lead to detrimental results.
Prolonged exposure to glutamate can promote a process
culminating in neuronal cell death [82, 150, 166, 167, 169,
171–173]. Accumulating evidence implicates glutamate
excitotoxicity in the pathophysiology of ALS. Further-
more, RNA editing impairments and a significant reduc-
tion in the expression and activity of the glutamate
transporter GLT1 in animal models of ALS and its human
counterpart EAAT2 in patients has been noted [174–178].
We can thus propose that reducing extracellular glutamate
levels around the susceptible neurons affected by gluta-
mate toxicity in ALS may mitigate the neurodegenerative
progression of the disease. Crossbreeding of SOD1 G93A
mice with astrocyte overexpressing human EAAT2 mice,
improved motor performance, protected motoneurons
from glutamate induced excitotoxicity but did not delay
the onset of paralysis nor did it prolong life span [179].
Transplantation of cells over-expressing GLT1 in animal
models of ALS should be investigated to maximize the
therapeutic potential of this approach.
Conclusions and future perspectives
To date there is no treatment that can substantially prolong
life expectancy in individuals afflicted with ALS. Never-
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theless where current drug treatments have failed, gene
therapy, cell replacement therapies or a combination of
both, could offer improved alternatives. Also, trophic
factors, known for their role in the survival, development
and maintenance of motor neurons [180–186] have been
considered as potential therapeutic agents in ALS. Encour-
aging preliminary results using neurotrophic factors in
animal models has prompted further research. Unfortunate-
ly, in clinical trials subcutaneous delivery of CNTF and
IGF-1 showed no clinical or survival benefits [77, 80–82].
However, more recent clinical trial infusing IGF-1 and
BDNF intrathecally found modest beneficial effects in ALS
patients with no severe adverse reactions [74–76, 79] which
indicate that further studies should be design.
Transplantation of stem cells genetically engineered or
otherwise induced to secrete such neurotrophic factors is
another viable therapeutic approach. Applying gene therapy
on stem cells prior to their transplantation to selectively
combine the therapeutic effect of neurotrophic factor
secretion and glutamate uptake might prove to provide the
best survival chances of degeneration prone neurons, to
ameliorate symptoms and reduce degeneration in ALS
patients. In the case of fALS, a limited subset of ALS
patients, the genetic bases of the disease is known and a
more personalized treatment regime, such as RNA based
silencing of the mutant SOD1 or other ALS related genes
(e.g. TARDBP, ALS2 and ALS4 genes), should be
considered.
A different therapeutic approach that may have the
potential to modify the progression of ALS is a design of
iron chelating multifunctional molecules. Indeed, preclinical
studies with the novel multimodal iron chelating compound,
M30, provide clear beneficial neuroprotective effects at the
pre-symptomatic phase and at relatively advanced stage of
the neurological dysfunctions. Further development of
efficient neuroprotective drugs for early treatment along
with early diagnostic of ALS patients is significant, since
up-to-date almost all ALS patients are diagnosed after
symptom onset. In view of the neuritogenic effect of M30
and its regulation of neurotrophic factors in motoneuron
cells, it is possible that in vivo pro-survival effect of M30 is
mediated through the regeneration process of motor nerves,
inducing neuro-differentiation and sprouting of axons,
leading to reinnervation of muscle fibers. Getting insight
the molecular mechanism of the drug will assist in the
translation of its protective effect from animal preclinical
studies into human ALS. Since the process of motoneuron
degeneration in ALS is complex and multifactorial, future
studies should consider the use of multifunctional iron
chelating drugs, such as M30 and HLA20, alone or in
combination with other compounds. These compounds
should be directed against distinct pathological mecha-
nisms (e.g. anti-glutamergic drug, riluzole) and non-
pharmaceutical approaches (e.g. highly energetic diet,
moderated exercises) in other models of motoneuron
degeneration, to develop the optimal neuroprotective
treatment for ALS. The implication of multifunctional
drug or “cocktail" therapies for ALS, together with a
pathology-specific and patient-specific manner, may pro-
vide efficient tools against the significant heterogeneity at
the molecular level and the population of ALS patients, to
make progress in overcoming this disease.
Preclinical neuroprotective studies are planned with the
intent of designing personalized medicine in which clini-
cians can tailor therapies to maximize benefit and minimize
risk. Taken together, the therapeutic approaches outlined in
this review, including multifunctional molecules, gene
therapy and stem cell-based therapies could possibly form
a beacon of hope for those patients suffering from ALS.
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